PTC Therapeutics (PTCT)
(Real Time Quote from BATS)
$32.50 USD
+3.93 (13.76%)
Updated Apr 29, 2024 01:06 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Brokerage Reports
0 items in cart
PTC Therapeutics, Inc. [PTCT]
Reports for Purchase
Showing records 81 - 100 ( 147 total )
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
NHS-England Delay Is Not Translarna Specific
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Program Advances, Triggering a $10M Milestone
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
3Q Corporate Update to Focus on Translarna
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
SMA Program Readthrough and Adjusting Estimates Post Financing
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Emerging Natural History Data Support Phase 3 Assumptions
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Small Molecules, Big Opportunities - Target to $58
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
Ataluren Phase 3 Fully Enrolled, Accelerated Approval Could Be Next
Provider: Roth Capital Partners, Inc.
Analyst: CHATTOPADHYAY D
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: PTC Therapeutics, Inc.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.